# Swiss Cancer Institute: Phase 3 study started recruiting, 230 planned (Metastatic NSCLC - Non-Small Cell Lung Cancer)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Swiss Cancer Institute |
| Sponsor type | Academic and hospital |
| Study | Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) |
| NCT ID | NCT07149649 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Metastatic NSCLC - Non-Small Cell Lung Cancer |
| Intervention types | drug, other |
| Target enrollment | 230 |
| Site countries | Switzerland |
| Posted | 2025-09-02 |
| Planned start | 2026-09-29 |
| Event | Started recruiting |
| Event date | 2026-09-29 |
| Last update posted | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 230 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07149649). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.